Volume 30, Issue 138 (January & February 2022)                   J Adv Med Biomed Res 2022, 30(138): 24-29 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sharifi Nasab M, Yazdimoghaddam H, Mohaddes S T, Rakhshani M H. Association between Diabetes and Controlling Risk Factors with Survival Rate in Colorectal Cancer. J Adv Med Biomed Res 2022; 30 (138) :24-29
URL: http://journal.zums.ac.ir/article-1-6217-en.html
Association between Diabetes and Controlling Risk Factors with Survival Rate in Colorectal Cancer
Marjan Sharifi Nasab1 , Hamide Yazdimoghaddam * 2, Seyedeh Tahereh Mohaddes3 , Mohammad Hasan Rakhshani4
1- Dept. of Nursing, Faculty of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran
2- Dept. of Operating Room, Faculty of Paramedics, Sabzevar University of Medical Sciences, Sabzevar, Iran , ha_yazdimoghaddam@yahoo.com
3- Dept. of Hematology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4- Dept. of Biostatistics and Epidemiology, School of Public Health, Sabzevar University of Medical Sciences, Sabzevar, Iran
Abstract:   (111487 Views)

Background and Objective: Colorectal cancer (CRC) is a highly prevalent malignancy leading to death across the world. However, patient survival is greatly affected following a diagnosis of diabetes. The purpose of this research was to study the correlation between diabetes and controlling risk factors with the survival rate of colorectal cancer patients.
Materials and Methods: This retrospective follow‐up study was done on 356 patients with colorectal cancer, who had been diagnosed during 1999-2013. Notably, the patients were selected using systematic random sampling. The patients were allocated into two groups according to the history of diabetes and its absence. The survival rate of the patients was assessed during the follow-up period up to 2018.
Results: In colorectal cancer patients, the diabetes prevalence was 11%. The mean survival rate in patients with CRC and non-colorectal non-diabetic was 5.541±0.227 years and in diabetic patients was 0.508 ±5.246 years. No significant difference was apperceived in the survival rate of the diabetic and non-diabetic patients (P = 0.57). The risk of mortality in patients with CRC who were not treated with insulin increased and their survival decreased (P= 0.05). In metastatic stage of lymph nodes, it was 0.314 higher in patients with the metastasis to distant regions (P = 0.000).
Conclusion: Based on the results, training diabetic patients regarding effective therapies in controlling risk factors, hyperglycemia, and screening for rapid diagnosis of CRC are essential to improve health and increase survival rate in diabetic patients.

Keywords: Diabetes Mellitus, Insulin, Survival, Colorectal Neoplasms, Neoplasm Metastasis
Full-Text [PDF 254 kb]   (107134 Downloads) |   |   Full-Text (HTML)  (1795 Views)  

✅ Based on the results, training diabetic patients regarding effective therapies in controlling risk factors, hyperglycemia, and screening for rapid diagnosis of CRC are essential to improve health and increase survival rate in diabetic patients.
 


Type of Study: Original Article | Subject: Health improvement strategies
Received: 2020/09/12 | Accepted: 2021/01/25 | Published: 2021/10/17
References
1. Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018 29(4):1016-22. [DOI:10.1093/annonc/mdy033] [PMID]
2. Dolatkhah R, Somi MH, Kermani IA, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC public health. 2015 15(1):997. [DOI:10.1186/s12889-015-2342-9] [PMID] [PMCID]
3. Kasper DL, Hauser SL, Fauci AS, et al. Harrisons internal medicine. 19th, editor. United States of America: MCGraw-Hill; 2015.
4. Organization WH. Country Cancer Profile. Available from: http://www who int/cancer/country-profiles/chn_en pdf. 2014 [Accessed 5 may 2021].
5. Pourhoseingholi MA, Zali MR. Colorectal cancer screening: Time for action in Iran. World J Gastrointest Oncol. 2012;4(4):82-3. [DOI:10.4251/wjgo.v4.i4.82] [PMID] [PMCID]
6. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]
7. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801. [DOI:10.1016/S1470-2045(12)70211-5]
8. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010 19(8):1893-907. [DOI:10.1158/1055-9965.EPI-10-0437] [PMID]
9. Wild S. Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations. Diabetologia. 2011;54(7):1589-92. [DOI:10.1007/s00125-011-2169-6] [PMID]
10. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967-81. [DOI:10.1007/s10552-012-9972-3] [PMID] [PMCID]
11. Collins KK. The diabetes-cancer link. Diabetes Spectr. 2014;27(4):276-80. [DOI:10.2337/diaspect.27.4.276] [PMID] [PMCID]
12. Fedeli U, Zoppini G, Gennaro N, et al. Diabetes and cancer mortality: a multifaceted association. Diabetes research and clinical practice. 2014;106(3):e86-e9. [DOI:10.1016/j.diabres.2014.09.027] [PMID]
13. Pandey A, Forte V, Abdallah M, et al. Diabetes mellitus and the risk of cancer. Minerva endocrinologica. 2011;36(3):187-209.
14. Call R, Grimsley M, Cadwallader L, et al. Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med. 2010;122(3):158-65. [DOI:10.3810/pgm.2010.05.2153] [PMID]
15. Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131(3):752-9. [DOI:10.1002/ijc.26421] [PMID]
16. Behrouzi B, Mohagheghi MA, Sadighi S. Demographic Characteristics, Survival and Prognostic Factors of Early Breast Cancer Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cohort Study. APJCP. 2017; 18(9):2485.
17. Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4(4):71. [DOI:10.4251/wjgo.v4.i4.71] [PMID] [PMCID]
18. Karlin NJ, Amin SB, Kosiorek HE, et al. Survival and glycemic control in patients with colorectal cancer and diabetes mellitus. Future Sci OA. 2018; 4(9):FSO335. [DOI:10.4155/fsoa-2018-0044] [PMID] [PMCID]
19. De Bruijn K, Arends L, Hansen B, et al. Systematic review and meta‐analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100(11):1421-9. [DOI:10.1002/bjs.9229] [PMID]
20. Rosato V, Tavani A, Gracia-Lavedan E, et al. Type 2 diabetes, antidiabetic medications, and colorectal cancer risk: two case-control studies from Italy and Spain. Front Oncol. 2016;6:210. [DOI:10.3389/fonc.2016.00210] [PMID] [PMCID]
21. Dąbrowski M, Szymańska-Garbacz E, Miszczyszyn Z, et al. Risk factors for cancer development in type 2 diabetes: A retrospective case-control study. BMC cancer. 2016;16(1):785. [DOI:10.1186/s12885-016-2836-6] [PMID] [PMCID]
22. Ramteke P, Deb A, Shepal V, et al. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers. 2019; 11(9):1402. [DOI:10.3390/cancers11091402] [PMID] [PMCID]
23. Ahmadi A, Mobasheri M, Hashemi Nazari SS. Survival time and relative risk of death in patients with colorectal cancer in an Iranian population: a cohort study. J Mazandaran Univ Med Sci. 2014;24(111):2-8.
24. Tahmasbi B, Abedi G, Moosazadeh M, et al. Determining the survival rate of colorectal cancer in Iran: A systematic review and meta-analysis. Asian Pacific journal of cancer prevention: APJCP. 2018; 19(11):3009. [DOI:10.31557/APJCP.2018.19.11.3009] [PMID] [PMCID]
25. Akhoond MR, Kazemnejad A, Hajizadeh E, et al. Comparison of colon and rectum cancer:survival and prognostic factors. Gastroenterol Hepatol Bed Bench. 2010;3:177-86.
26. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011;29(1):54-60. [DOI:10.1200/JCO.2010.29.3183] [PMID] [PMCID]
27. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine. 2010;38(11):602-6. [DOI:10.1016/j.mpmed.2010.08.007]
28. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62(6):933-47. [DOI:10.1136/gutjnl-2013-304701] [PMID]
29. Murphy TK, Calle EE, Rodriguez C, et al. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847-54. [DOI:10.1093/aje/152.9.847] [PMID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb